financetom
Business
financetom
/
Business
/
Rockwell Automation Defies Q1 Sales Decline With Cost Discipline And Strong Cash Flow; Stock Jumps
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rockwell Automation Defies Q1 Sales Decline With Cost Discipline And Strong Cash Flow; Stock Jumps
Feb 10, 2025 7:55 AM

Rockwell Automation, Inc. ( ROK ) shares surged after the company reported better-than-expected first-quarter results.

Sales fell 8.4% year over year and slid 7.6% organically to $1.881 billion, in line with the consensus of $1.881 billion.

Segment Details: Intelligent Devices sales declined 13.1% to $806 million, Software & Control fell 12.4% to $529 million, and Lifecycle Services rose 5% to $546 million.

Total ARR grew 11%. Adjusted EPS was $1.83 (-10% YoY), above the analyst consensus of $1.59.

Total segment operating earnings for the quarter fell 10% year-over-year to $321 million. Segment operating margin declined slightly to 17.1% from 17.3%, impacted by lower sales volume, though partially offset by cost reductions and margin expansion efforts.

Operating cash flow was $364 million, up from $33 million year over year. Free cash flow reached $293 million, compared to a $35 million outflow last year. The increase was mainly due to no payout of incentive compensation in the first quarter of fiscal 2025 related to fiscal 2024 performance.

“From a demand perspective, we are encouraged by better-than-expected order performance in the quarter with sequential growth across all regions and business segments. While there is still some macroeconomic and policy uncertainty weighing on customers' capex plans, Rockwell won multi-million dollar strategic orders across key industries, especially in the U.S., our home market,” commented Blake Moret, Chairman and CEO.

“Q1 margins and EPS came in well above our expectations this quarter, reflecting some early benefits of Rockwell’s renewed focus on operational excellence and cost discipline,” added Moret.

The company repurchased 0.4 million shares for $99 million during the quarter. As of December 31, $1.2 billion remained under existing repurchase authorizations.

Return on Invested Capital for the twelve months ended December 31, 2024, was 14.5%, down from 18.5% in the prior year, primarily due to lower pre-tax net income.

FY25 Outlook updates: Rockwell continues to expect adjusted EPS of $8.60 – $9.80 versus the $9.40 estimate.

The company lowered sales midpoint expectations to ~$8.1 billion from the prior view of ~$8.2 billion versus the $8.225 billion estimate.

The company updated fiscal 2025 reported sales growth range to (5.5)% – 0.5% due to ~(1.5)% FX impact to sales, reaffirmed organic sales growth range of (4)% – 2%.

Price Action: ROK shares are trading higher by 9.36% at $293.51 at the last check Monday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
RH's H2 Sales Guidance 'Less Achievable' As Demand Decelerated, Says Wedbush
RH's H2 Sales Guidance 'Less Achievable' As Demand Decelerated, Says Wedbush
Sep 6, 2024
08:48 AM EDT, 09/06/2024 (MT Newswires) -- RH's (RH) demand growth for 2024 is expected to be in line with its guidance of 9% to 10% year over year growth; however, it likely overestimated its H2 sales guidance, Wedbush analysts said in a note Friday. The analysts said they believe that RH's guidance for a very sharp double-digit rise in...
DSV ahead in bidding for Deutsche Bahn's Schenker, sources say
DSV ahead in bidding for Deutsche Bahn's Schenker, sources say
Sep 6, 2024
BERLIN (Reuters) - Danish transport firm DSV is slightly ahead in the bidding race for German state railway Deutsche Bahn's logistics unit Schenker, several people familiar with the sales process told Reuters on Friday. DSV's offer is currently seen as the most attractive, the sources said after a meeting of a government committee that evaluated the bid along with a...
Ventyx Biosciences Doses First Patient in Phase 2a Parkinson's Drug Trial
Ventyx Biosciences Doses First Patient in Phase 2a Parkinson's Drug Trial
Sep 6, 2024
09:00 AM EDT, 09/06/2024 (MT Newswires) -- Ventyx Biosciences ( VTYX ) said Friday it has dosed the first patient in a phase 2a trial of its drug candidate VTX3232 for early-stage Parkinson's disease. The company said the study will assess the safety and tolerability of VTX3232, a selective NLRP3 inhibitor, over a 28-day treatment period involving about 10 patients....
Guidewire Q4 Beats Estimates, Revenue And ARR Surge
Guidewire Q4 Beats Estimates, Revenue And ARR Surge
Sep 6, 2024
Guidewire Software, Inc. ( GWRE ) shares are trading higher after the company reported fourth-quarter results on Thursday. Total revenue rose 8% Y/Y to $291.5 million, beating the consensus of $283.9 million. Subscription and support revenue increased by 29% Y/Y to $151.8 million, while license revenue decreased by 12% Y/Y to $88.9 million. Also, Services revenue fell by 2% to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved